Quantifying bone quality through touch.

Active Life Scientific is an early-stage medical device company that has developed a fundamentally new approach to understanding bone health and quality. We’ve harnessed the power of touch to create a handheld device that can directly measure bone material quality. We believe that measuring bone material quality is important for a complete assessment of skeletal health and will help physicians manage their patients better.

OsteoProbe quantifies bone quality.

Quality is something you can feel. Our sense of touch intuitively tells us about quality. Physicians learn to use their sense of touch on a regular basis to make decisions, but the sense of touch has never been quantified. We have developed the OsteoProbe, a handheld device that can quantify material aspects of bone quality using the power of touch.

Immediate Results

Each patient's Bone Score™ is available immediately after assessment.


Assessment takes less than 5 minutes during a routine office exam.


The device is handheld and the entire kit fits into a small briefcase.

Bone quality is the missing piece of the puzzle.

There's more to bone strength than meets the eye.

Bone strength is multifaceted. Strong bone has good structure, adequate density, and good material quality. Currently bone strength is only assessed through indirect imaging methods. Material quality is the missing piece of the puzzle because it cannot be quantified clinically.

Determining bone strength requires touch.

Measuring bone material quality has never been possible by indirect methods. A direct approach is required. By safely and gently touching bone tissue, it is now possible to quantify quality.

The puzzle of bone fragility is a real problem.

Low BMD is not the cause of fragility for certain populations.

Disorders that affect bone mineral homeostasis or collagen, imbalances in bone remodeling, and certain treatments can dramatically increase fragility without commensurate changes in bone mineral density (BMD).

Most fragility fractures occur in patients with non-osteoporotic BMD.

Clinical evidence suggests the majority of fragility fractures occur for patients without osteoporotic bone mineral density (BMD).


Learn how the Bone Score™ was developed and validated as a measure of bone quality.


Learn about our vision to transform bone healthcare.

Get Involved

Help us transform bone healthcare with your research.

We'd love to hear from you.

Click here to contact us about your interest in OsteoProbe.